

# Neuropathic Ocular Pain (NOP)??”Epidemiology Forecast??“2032

<https://marketpublishers.com/r/NE1F67FE04F0EN.html>

Date: January 2022

Pages: 60

Price: US\$ 3,950.00 (Single User License)

ID: NE1F67FE04F0EN

## Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Neuropathic Ocular Pain (NOP) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Neuropathic Ocular Pain (NOP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

### Geographies Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019-2032

### Neuropathic Ocular Pain (NOP) Understanding

The DelveInsight Neuropathic Ocular Pain (NOP) epidemiology report gives a thorough understanding of the Neuropathic Ocular Pain (NOP) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Neuropathic Ocular Pain (NOP) in the US, Europe, and Japan. The report covers the detailed information of the Neuropathic Ocular Pain (NOP) epidemiology scenario in seven major countries (US, EU5, and

Japan).

## Neuropathic Ocular Pain (NOP) Epidemiology Perspective by DelveInsight

The Neuropathic Ocular Pain (NOP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Neuropathic Ocular Pain (NOP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Neuropathic Ocular Pain (NOP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

## Neuropathic Ocular Pain (NOP) Detailed Epidemiology Segmentation

The Neuropathic Ocular Pain (NOP) epidemiology covered in the report provides historical as well as forecasted Neuropathic Ocular Pain (NOP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Neuropathic Ocular Pain (NOP) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

## Scope of the Report

The Neuropathic Ocular Pain (NOP) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

The Neuropathic Ocular Pain (NOP) Epidemiology Report and Model provide an overview of the global trends of Neuropathic Ocular Pain (NOP) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

The report provides insight into the historical and forecasted patient pool of Neuropathic Ocular Pain (NOP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

The report helps recognize the growth opportunities in the 7MM for the patient population

The report assesses the disease risk and burden and highlights the unmet needs of Neuropathic Ocular Pain (NOP)

The report provides the segmentation of the Neuropathic Ocular Pain (NOP) epidemiology

## Report Highlights

11-year Forecast of Neuropathic Ocular Pain (NOP) epidemiology

7MM Coverage

Prevalent and Diagnosed Cases of Neuropathic Ocular Pain (NOP)

Cases of Neuropathic Ocular Pain (NOP) by Mutation Types

Neuropathic Ocular Pain (NOP) Cases associated with Clinical Manifestations

## KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

## Key Questions Answered

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Neuropathic Ocular Pain (NOP)?

What are the key findings pertaining to the Neuropathic Ocular Pain (NOP) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?

What would be the total number of patients of Neuropathic Ocular Pain (NOP) across the 7MM during the forecast period (2019-2032)?

Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?

At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

What is the disease risk, burden and unmet needs of Neuropathic Ocular Pain (NOP)?

What are the currently available treatments of Neuropathic Ocular Pain (NOP)?

## Reasons to buy

The Neuropathic Ocular Pain (NOP) Epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global Neuropathic Ocular Pain (NOP) market

Quantify patient populations in the global Neuropathic Ocular Pain (NOP) market to improve product design, pricing, and launch plans

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Neuropathic Ocular Pain (NOP) therapeutics in each of the markets covered

Understand the magnitude of Neuropathic Ocular Pain (NOP) population by its epidemiology

The Neuropathic Ocular Pain (NOP) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

## Key Assessments

Patient Segmentation

Disease Risk & Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

## Contents

### 1. KEY INSIGHTS

### 2. EXECUTIVE SUMMARY OF NEUROPATHIC OCULAR PAIN (NOP)

### 3. NEUROPATHIC OCULAR PAIN (NOP): DISEASE BACKGROUND AND OVERVIEW

#### 3.1. Introduction

#### 3.2. Sign and Symptoms

#### 3.3. Pathophysiology

#### 3.4. Risk Factors

#### 3.5. Diagnosis

### 4. PATIENT JOURNEY

### 5. EPIDEMIOLOGY AND PATIENT POPULATION

#### 5.1. Epidemiology Key Findings

#### 5.2. Assumptions and Rationale: 7MM

#### 5.3. Epidemiology Scenario: 7MM

##### 5.3.1. Neuropathic Ocular Pain (NOP) Epidemiology Scenario in the 7MM (2019-2032)

#### 5.4. United States Epidemiology

##### 5.4.1. Neuropathic Ocular Pain (NOP) Epidemiology Scenario in the United States (2019- 2032)

#### 5.5. EU-5 Country-wise Epidemiology

##### 5.5.1. Germany Epidemiology

###### 5.5.1.1. Neuropathic Ocular Pain (NOP) Epidemiology Scenario in Germany (2019-2032)

##### 5.5.2. France Epidemiology

###### 5.5.2.1. Neuropathic Ocular Pain (NOP) Epidemiology Scenario in France (2019-2032)

##### 5.5.3. Italy Epidemiology

###### 5.5.3.1. Neuropathic Ocular Pain (NOP) Epidemiology Scenario in Italy (2019- 2032)

##### 5.5.4. Spain Epidemiology

###### 5.5.4.1. Neuropathic Ocular Pain (NOP) Epidemiology Scenario in Spain (2019-2032)

#### 5.5.5. United Kingdom Epidemiology

5.5.5.1. Neuropathic Ocular Pain (NOP) Epidemiology Scenario in the United Kingdom (2019-2032)

#### 5.6. Japan Epidemiology

5.6.1. Neuropathic Ocular Pain (NOP) Epidemiology Scenario in Japan (2019- 2032)

### **6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES**

6.1. Neuropathic Ocular Pain (NOP) Treatment and Management

6.2. Neuropathic Ocular Pain (NOP) Treatment Algorithm

### **7. KOL VIEWS**

### **8. UNMET NEEDS**

### **9. APPENDIX**

9.1. Bibliography

9.2. Report Methodology

### **10. DELVEINSIGHT CAPABILITIES**

### **11. DISCLAIMER**

### **12. ABOUT DELVEINSIGHT**

\*The table of contents is not exhaustive; will be provided in the final report

## List Of Tables

### LIST OF TABLES

List of Table:

Table 1: Neuropathic Ocular Pain (NOP) Epidemiology in 7MM (2019-2032)

Table 2: Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in 7MM (2019-2032)

Table 3: Neuropathic Ocular Pain (NOP) Epidemiology in the United States (2019-2032)

Table 4: Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Neuropathic Ocular Pain (NOP) Epidemiology in Germany (2019-2032)

Table 6: Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Neuropathic Ocular Pain (NOP) Epidemiology in France (2019-2032)

Table 8: Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Neuropathic Ocular Pain (NOP) Epidemiology in Italy (2019-2032)

Table 10: Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Neuropathic Ocular Pain (NOP) Epidemiology in Spain (2019-2032)

Table 12: Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Neuropathic Ocular Pain (NOP) Epidemiology in the United Kingdom (2019-2032)

Table 14: Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Table 15: Neuropathic Ocular Pain (NOP) Epidemiology in Japan (2019-2032)

Table 16: Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in Japan (2019-2032)



## List Of Figures

### LIST OF FIGURES

#### List of Figures

Figure 1 Neuropathic Ocular Pain (NOP) Epidemiology in 7MM (2019-2032)

Figure 2 Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in 7MM (2019-2032)

Figure 3 Neuropathic Ocular Pain (NOP) Epidemiology in the United States (2019-2032)

Figure 4 Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5 Neuropathic Ocular Pain (NOP) Epidemiology in Germany (2019-2032)

Figure 6 Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7 Neuropathic Ocular Pain (NOP) Epidemiology in France (2019-2032)

Figure 8 Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in France (2019-2032)

Figure 9 Neuropathic Ocular Pain (NOP) Epidemiology in Italy (2019-2032)

Figure 10 Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11 Neuropathic Ocular Pain (NOP) Epidemiology in Spain (2019-2032)

Figure 12 Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13 Neuropathic Ocular Pain (NOP) Epidemiology in the United Kingdom (2019-2032)

Figure 14 Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Figure 15 Neuropathic Ocular Pain (NOP) Epidemiology in Japan (2019-2032)

Figure 16 Neuropathic Ocular Pain (NOP) Diagnosed and Treatable Cases in Japan (2019-2032)

\*The table of contents is not exhaustive; will be provided in the final report

## I would like to order

Product name: Neuropathic Ocular Pain (NOP)??"Epidemiology Forecast??"2032

Product link: <https://marketpublishers.com/r/NE1F67FE04F0EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NE1F67FE04F0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970